Poseida Form 8-K P-PSMA-101 Update

On August 17, 2020, Poseida Therapeutics, Inc. (the “Company”) announced that following notification to the U.S. Food and Drug Administration (FDA) of a pause in enrollment pursuant to the protocol to investigate a patient death, it has received communication from the FDA that the Company’s Phase 1 clinical trial for P-PSMA-101 in metastatic castrate resistant prostate cancer has been placed on clinical hold.